Page 173 - Academic Press Encyclopedia of Physical Science and Technology 3rd BioTechnology
P. 173

P1: GKY/GLQ/GTK  P2: GLM Final Pages
 Encyclopedia of Physical Science and Technology  en009I-422  July 6, 2001  19:57







              Metabolic Engineering                                                                       401

              and combined with transcription profiling this may give  55 billion US$. Table III lists some typical fermentation
              important information about regulation at the differ-  products categorized according to their synthesis route,
              ent levels. Finally, powerful analytical techniques like  i.e., whether they are whole cells, derived from the pri-
              GC-MS and LC-MS-MS (LC: liquid chromatography)    mary or secondary metabolism, are specifically synthe-
              enable measurement of a large fraction of the intracel-  sized (and perhaps secreted) proteins, large polymers, or
              lular metabolite—often referred to as the metabolome. As  genetic material. Clearly, the strategy for improving the
              discussed above, the intracellular metabolite concentra-  productivity depends much on whether the product is syn-
              tions give unique information about the control of fluxes,  thesized by the action of many enzymatic steps or whether
              and therefore represent a very detailed phenotypic char-  the product is derived directly from expression of a sin-
              acterization. There is still, however, some significant de-  gle gene. Furthermore, for high value added products like
              velopments required before these methods enable high-  pharmaceutical proteins, time to market is often more im-
              throughput, quantitative analysis of many metabolites.  portant than obtaining a high yield or high productivity,
                                                                which on the other hand are essential for optimization of
                                                                processesleadingtolow-valueaddedproductslikeethanol
              VII. APPLICATIONS OF METABOLIC                    and many antibiotics. Despite these differences, the mind-
                  ENGINEERING                                   set of metabolic engineering is still extremely valuable in
                                                                optimization of any fermentation processes, as discussed
              Today metabolic engineering is applied in the optimiza-  further in the following.
              tion of almost all fermentation processes, and the total  In recent years there have been reported on many exam-
              market value of fermentation-derived products exceeds  ples of metabolic engineering, and these examples can be


                          TABLE III List of Some Fermentation Products and Some Market Volumes
                          Category of product    Product           Typical organism
                          Whole cells       Baker’s yeast      S. cerevisiae
                                            Lactic acid bacteria  Lactic acid bacteria
                                            Single cell protein  Methanogenic bacteria
                          Primary metabolites  Ethanol         S. cerevisiae, Z. mobilis  12 billion US$
                                            Lactic acid        Lactic acid bacteria, R. oryzae  200 million US$
                                            Citric acid        A. niger                1.5 billion US$
                                            Glutamate          C. glutamicum           1 billion US$
                                            Lysine             C. glutamicum           500 million US$
                                            Phenylalanine      E. coli                 200 million US$
                          Secondary metabolites  Penicillins   P. chrysogenum          4 billion US$
                                            Cephalosporins     A. chrysogenum, S. clavuligerus  11 billion US$
                                            Statins            Aspergillus             9 billion US$
                                            Taxol              Plant cells             1 billion US$
                          Recombinant proteins  Insulin        S. cerevisiae, E. coli  3 billion US$
                                            tPA                CHO cells a             1 billion US$
                                            Erythropoitin      CHO cells               3.6 billion US$
                                            Human growth hormone  E. coli              1 billion US$
                                            Interferons        E. coli                 2 billion US$
                                            Vaccines           Bacteria and yeast
                                            Monoclonal antibodies  Hybridoma cells     700 million US$
                          Enzymes           Detergent enzymes  Bacillus, Aspergillus   600 million US$
                                            Starch industry    Aspergillus             200 million US$
                                            Chymosin           Aspergillus
                          Polymers          Xanthan gum        X. campestris           400 million US$
                                            Polyhydroxybutyrates
                          DNA               Vaccines           E. coli
                                            Gene therapy       E. coli
                            a  Chinese hamster ovary cells.
   168   169   170   171   172   173   174   175   176   177   178